V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Personalis Executive Compensation (FY25)

PSNL · Executive and director compensation, fiscal 2024 to 2025

The paid brief on Personalis

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 21, 2026Latest filing (8-K): May 13, 2026
6 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Personalis brief$1,500Get the executive brief
106 figures on this page: 101 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Christopher Hall
Latest say-on-pay support
=
May 12, 2026

More on Personalis

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Christopher Hall: $1,535,960 → $3,505,978 (128.3% higher)
Say-on-pay support: 96.2% → 99.5% (3.3 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Personalis' chief executive and what were they paid?
Christopher Hall, Chief Executive Officer and Director, received $3,505,978 in total compensation for fiscal 2025. Hall's total moved 128.3% higher from the $1,535,960 reported for fiscal 2024.
What was Personalis' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 99.5% of votes cast for or against in favor at the meeting held May 12, 2026.
Which companies are in Personalis' peer group?
Companies named in the disclosed peer group include Adaptive Biotechnologies 1, Akoya Biosciences, Akoya Biosciences 1, Alector and Biodesix, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Hall
Chief Executive Officer and Director
◇——◇◇—◇◇
Aaron Tachibana
Chief Financial Officer and Chief Operating Officer
◇——◇◇—◇◇
Richard Chen
President, Executive Vice President, Research and Development and Chief Medical Officer
◇——◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Hall
Chief Executive Officer and Director
◇—◇◇◇—◇◇
Aaron Tachibana
Chief Financial Officer and Chief Operating Officer
◇—◇◇◇—◇◇
Richard Chen
President, Executive Vice President, Research and Development and Chief Medical Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Richard ChenOption◇—◇3/15/2035
Option◇—◇3/15/2034
Option◇—◇3/15/2033
PSU◇◇——
Aaron TachibanaOption◇—◇3/15/2035
Option◇—◇3/15/2034
Option◇—◇3/15/2033
PSU◇◇——
Christopher HallOption◇—◇3/15/2035
Option◇—◇3/15/2034
Option◇—◇3/15/2033
Option◇—◇10/31/2032
RSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Karin Eastham
◇—◇———◇
Olivia K. Bloom
◇—◇———◇
A. Blaine Bowman
◇—◇———◇
Woodrow Myers Jr., M.D
◇—◇———◇
Lonnie Shoff
◇—◇———◇
Christopher Hall served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Adaptive Biotechnologies 1 ADPT
  • Akoya Biosciences AKYA
  • Akoya Biosciences 1 symbol not shown
  • Alector ALEC
  • Biodesix symbol not shown
  • CareDx CDNA
  • Castle Biosciences CSTL
  • Codexis CDXS
  • CytomX Therapeutics CTMX
  • Fulgent Genetics 1 FLGT
  • GeneDx WGS
  • Mesa Laboratories 1 MLAB
  • OraSure Technologies OSUR
  • Pacific Biosciences of California PACB
  • Quanterix QTRX
  • Standard BioTools LAB
  • Sutro Biopharma 1 STRO
  • Twist Bioscience 1 TWST
  • Veracyte VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 12, 2026=◇◇◇
2024May 16, 2025=◇◇◇
2023May 17, 2024=◇◇◇
2022May 17, 2023=◇◇◇
2021May 17, 2022=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Personalis files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Personalis disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Personalis sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Personalis' disclosed peer group is defensible, who names Personalis back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
106 figures on this page: 101 cited to the filing that reported them, 5 calculated from figures it prints.
101 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001193125-26-221846
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-140038
    DIRECTOR COMPENSATION
  3. 0000950170-25-074346
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-24-062886
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0000950170-23-023232
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001564590-22-020773
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Personalis executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/PSNL (accessed 2026).
Short form: data: Velarion

The paid brief for Personalis

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Personalis and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Personalis discloses

The companies named in PSNL's own disclosed peer group.

Adaptive Biotechnologies 1AlectorCareDxCastle BiosciencesCodexisFulgent Genetics 1GeneDxMesa Laboratories 1OraSure TechnologiesPacific Biosciences of CaliforniaQuanterixStandard BioToolsSutro Biopharma 1Twist Bioscience 1Veracyte

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy